ClinicalTrials.Veeva

Menu

Comparison of the Efficacy of Accelerated Intermittent Theta Burst Stimulation and Accelerated Continuous Theta Burst Stimulation in Patients With Treatment-Resistant Depression

A

Ataturk University

Status

Enrolling

Conditions

Continuous Theta Burst Stimulation
Accelerated Protocol
Intermittent Theta Burst Stimulation
Treatment Resistant Depression (TRD)
Transcranial Magnetic Stimulation
Unilateral rTMS

Treatments

Device: Transcranial Magnetic Stimulation with figure-eight coil

Study type

Interventional

Funder types

Other

Identifiers

NCT07264452
2025-08/08
Atatürk University (Other Identifier)

Details and patient eligibility

About

In recent years, research on the effectiveness of transcranial magnetic stimulation (TMS) in patients with treatment-resistant depression (RTD) has been steadily increasing. The aim of this study was to examine the effectiveness of accelerated unilateral application of two different forms of theta burst stimulation (TBU), a variation of repetitive TMU (rTMS)-intermittent TBU (iTBU) and continuous TBU (cTBU)-in TDD patients. The study aimed to compare the advantages of iTBU and cTBU protocols on depression, suicidal thoughts, anxiety levels, sleep disturbances, cognitive performance, and overall functioning following a two-week intensive treatment period and a 12-week follow-up period.

Full description

Major depressive disorder (MDD) is the most common form of mood disorders that is frequently encountered in the society, has high recurrence and chronicity rates, and can lead to significant physical, cognitive, and psychosocial dysfunction in individuals. Although there is no single universally accepted definition for treatment-resistant depression (TRD), one of the most frequently used definitions is "failure to respond to at least two different antidepressant treatments for a sufficient duration and at an appropriate dose." Repetitive transcranial magnetic stimulation (rTMS) applied to the left and/or right dorsolateral prefrontal cortex (DLPFC) stands out as an alternative treatment approach in patients with TRD. One of these methods, theta-burst stimulation (TBS), is a non-invasive neuromodulation method approved by the US Food and Drug Administration (FDA) for treatment-resistant depression. Current methodological advances have enabled current TBS protocols to; Therapeutic efficacy can be enhanced by applying sessions multiple times a day, increasing the stimulation dose, and more precisely targeting the bilateral DLPFC. In addition to intermittent TBS (iTBS), continuous TBS (cTBS) protocols applied to the right DLPFC have also been reported to offer therapeutic potential in patients with TDD. Several studies have demonstrated that protocols consisting of 1,800 pulses produce lasting changes in cortical excitability and effectively trigger targeted neuroplastic mechanisms.

The study was planned to be conducted with patients who presented to the Atatürk University Faculty of Medicine, Department of Psychiatry Outpatient Clinic and were diagnosed with major depressive disorder (MDD) according to the American Psychiatric Association's DSM-5 diagnostic criteria. Participants were randomly assigned to two groups. In this single-blind, parallel study, one group was scheduled to receive a total of 50 sessions of iTBS to the left dorsolateral prefrontal cortex (left-DLPFC), while the other group received 50 sessions of cTBS to the right-DLPFC.

Clinical assessments of patients will be conducted at baseline, mid-treatment, at the end of treatment, and at weeks 2, 4, 8, and 12 post-treatment. Depressive symptoms will be measured with the HAM-D and MADRS, anxiety with the Hamilton Anxiety Rating Scale (HAM-A), sleep disturbances with the Pittsburgh Sleep Quality Index (PSQI) and Insomnia Severity Index (ISI), cognitive functions with the Montreal Cognitive Assessment Scale (MoCA), and functioning with the Brief Functioning Assessment Scale (BFAS). Participants were expected to maintain their current psychotropic medication at stable doses throughout the study.

Enrollment

60 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. 18 to 65 years old
  2. Patients diagnosed with Major Depressive Disorder according to DSM 5 and the severity of their illness
  3. Scoring 7 points or more on the Maudsley staging method
  4. Having depression unresponsive to 2 different antidepressants
  5. No clinical mental retardation
  6. Agree to participate in the study
  7. Hamilton Depression Rating Scale-17 [HDRS] score of 20 or higher
  8. Montgomery Asberg Depression Rating Scale [MADRS] score of 20 or above
  9. Being right hand dominant
  10. Having used the same antidepressant at the same dose for the last 4 weeks

Exclusion criteria

  1. Diagnosed with a neurological or metabolic disease that affects cognitive functions (Systemic diseases such as diabetes mellitus, cardiovascular disease, cerebrovascular disease, chronic renal failure, Parkinson's disease, multiple sclerosis, polyneuropathy, inflammatory rheumatologic disease and malignancies)
  2. Having a foreign body such as a pacemaker, intracranial implant that can magnetically interact
  3. Hearing and visual impairments that prevent communication
  4. Unstable or acute medical conditions
  5. Pregnancy or breastfeeding
  6. Having a primary psychiatric disorder other than major depressive disorder
  7. Being diagnosed with severe MDD with psychotic features

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

60 participants in 2 patient groups

Itbs
Active Comparator group
Description:
iTBS with eight digit coils to the left dorsolateral prefrontal cortex.
Treatment:
Device: Transcranial Magnetic Stimulation with figure-eight coil
Device: Transcranial Magnetic Stimulation with figure-eight coil
ctbs
Active Comparator group
Description:
cTBS with a figure-of-eight coil to the right dorsolateral prefrontal cortex.
Treatment:
Device: Transcranial Magnetic Stimulation with figure-eight coil
Device: Transcranial Magnetic Stimulation with figure-eight coil

Trial contacts and locations

1

Loading...

Central trial contact

Omer Faruk UYGUR, Associate professor doctor; Mahmut Balamur, research assistant doctor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems